Covid19, SARS-CoV Infection
Conditions
Keywords
COVID-19, SARS-CoV2, sargramostim, Leukine, (recombinant human) GM-CSF, immune modulator, SCOPE
Brief summary
The purpose of this research is to understand if the study drug, also called sargramostim or Leukine®, can help prevent the worsening of COVID-19 when the study drug is inhaled. This study will also help researchers understand if inhaled sargramostim can help prevent visits to the emergency room or hospitalization, or death.
Detailed description
This Phase 2b, multicenter, placebo-controlled, double-blind study will randomize approximately 500 adult patients who are symptomatic with mild or moderate COVID-19 (as defined in the FDA Guidance Document: Covid-19: Developing Drugs and Biological Products for Treatment or Prevention, May 2020) who are at high risk for progression to more severe disease. Patients will be randomized in a 1:1 ratio to inhaled sargramostim plus standard of care (SOC) or placebo plus SOC. Enrollment of patients who have completed a COVID-19 vaccination regimen or participated in a COVID-19 vaccine clinical trial will be capped at approximately 100 patients. All patients will be randomized to receive either 250 mcg of sargramostim or equivalent volume of placebo diluent. Treatment will be administered once daily for 5 days delivered via a vibrating mesh nebulizer. Patients will be followed for up to 60 days after start of treatment. Sargramostim (Leukine) is a formulation of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), which is a critical cytokine for healthy pulmonary function. Detailed studies have shown that GM-CSF is necessary for alveolar macrophage (AM) maturation and maintenance. Although GM-CSF was discovered as a myelopoietic growth factor, it has diverse additional effects that both promote differentiation of myeloid precursors into neutrophils, monocytes, and dendritic cells and control function of mature myeloid cells. GM-CSF is also known to reverse immunoparalysis seen in sepsis, resulting in beneficial outcomes. In addition, GM-CSF prevents bacteremia in post influenza bacterial pneumonia through locally mediated improved lung antibacterial resistance and increased reactive oxygen species production by AMs. Pulmonary delivery of this GM-CSF has potential to reduce morbidity and mortality due to viral pneumonias, potentially including COVID-19.
Interventions
DRUGSargramostim
All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days.
DRUGPlacebo
All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.
Sponsors
United States Department of Defense
Partner Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Double blind
Intervention model description
This Phase 2b, multicenter, placebo-controlled, double-blind study will randomize approximately 500 adult patients who are symptomatic with mild or moderate COVID-19 (as defined in the FDA Guidance Document: Covid-19: Developing Drugs and Biological Products for Treatment or Prevention, May 2020) who are at high risk for progression to more severe disease. Patients will be randomized in a 1:1 ratio to inhaled sargramostim plus standard of care (SOC) or placebo plus SOC. Enrollment of patients who have completed a COVID-19 vaccination regimen or participated in a COVID-19 vaccine clinical trial will be capped at approximately 100 patients.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with a positive laboratory diagnosis of SARS-CoV-2 infection by an antigen or a molecular test ≤5 days prior to randomization. The test should have been authorized by the relevant regulatory authority. 2. Have one or more of the following mild or moderate COVID-19 symptoms for ≤5 days prior to randomization: 1. Fever or chills 2. New onset or worsening cough 3. Sore throat 4. Malaise or fatigue 5. Headache 6. Muscle pain (myalgias) or body aches 7. Gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) 8. New onset or worsening shortness of breath or difficulty breathing 9. Nasal congestion or runny nose 10. New loss of taste (ageusia) and/or smell (anosmia). Note: any of these symptoms (ageusia, anosmia) alone or in combination cannot be used as the SOLE qualifying symptoms for enrollment. 3. At higher risk for progression to more severe COVID-19 1. Age ≥ 60 years 2. Age 18-59 years with a clinically stable medical history of at least 1 or more of the following conditions that could lead to severe COVID-19: * Chronic respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis * Obesity with BMI ≥ 30 kg/m2 * Cardiovascular disease * Sickle cell disease or thalassemia * Diabetes mellitus being managed with concomitant medications * Hypertension being managed with concomitant medications * Chronic kidney disease 4. Oxygen saturation by pulse oximeter \> 93% on room air. Note: at altitudes of \>4000 feet above sea level, oxygen saturation by pulse oximeter \> 91% on room air is permitted 5. Negative pregnancy test (if woman of childbearing potential) 6. Females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods from screening to Day 28 7. The patient (or legally authorized decision maker) must give informed consent
Exclusion criteria
1. Hospitalized patients 2. Patients who have received or are receiving other treatments that are not approved/authorized by the relevant regulatory authority for the treatment of patients with mild or moderate COVID-19 in an outpatient setting 3. Patients enrolled in interventional clinical trials for other experimental therapies 4. Patients on chronic oxygen supplementation due to cardiopulmonary or other conditions 5. Patients with unstable comorbid conditions (e.g., decompensated congestive heart failure, COPD with exacerbation, current angina pectoris, uncontrolled diabetes mellitus, uncontrolled hypertension, uncontrolled asthma) 6. Patients with severe pulmonary comorbid conditions, including systemic steroid-dependent asthma, systemic steroid-dependent COPD, oxygen-dependent COPD, lung transplant, or cystic fibrosis 7. Patients who have received highly immunosuppressive therapy (to include systemic corticosteroids) or anti-cancer combination chemotherapy within 24 hours prior to first dose of study drug 8. Patients with known or suspected intolerance or hypersensitivity to sargramostim, or any component of the product 9. Patients who have previously experienced severe and unexplained side effects during aerosol delivery of any kind of medical product 10. Pregnant or breastfeeding females 11. Patients who, in the opinion of the Investigator, will not be able to comply with all the study procedures and visits as outlined in the schedule of events, including follow-up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With an Emergency Room Visit or Hospitalization, or Death by Day 28 | 28 days | Percentage of patients who experience any emergency room visit or hospitalization, or death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Progression Based on NIAID Score | Day 28 and Day 60 | Proportion of patients with any progression of disease as determined by a ≥ 2-point increase from baseline in the National Institute of Allergy and Infectious Disease (NIAID) Ordinal Scale up to Day 28, and Day 60. The NIAID Ordinal Scale is a 1-8 scale and is an assessment of clinical status on a given study day. A score of 1 indicates the patient is not hospitalized and has no limitations on activities. A score of 8 indicates the patient has died. |
| Time to Disease Progression Based on NIAID Score | Day 28 and Day 60 | Time to progression of disease as determined by a ≥ 2-point increase in the NIAID ordinal scale up to Day 28, and Day 60. The NIAID ordinal scale is a 1-8 scale and is an assessment of clinical status on a given study day. A score of 1 indicates the patient is not hospitalized and has no limitations on activities. A score of 8 indicates the patient has died. |
| Change From Baseline in Overall Symptom Scores | Day 7, 14, and 28 | Change from baseline in overall symptom score as measured by the Symptom Score Questionnaire on Day 7, Day 14 and Day 28. The overall symptom score is the sum of 14 individual symptom scores from Symptom Score Questionnaire. Individual symptom scores correspond to the following responses: None = 0, Mild = 1, Moderate = 2, Severe = 3; None = 0, 1-2 times = 1, 3-4 times = 2, 5 or more times = 3; Same as usual = 0, Less than usual = 1, No sense = 2. The lowest score could be 0, and the highest score could be 42. Patients with higher scores have more severe symptoms from COVID-19. |
| Number of Participants With Adverse Events | 60 days | Adverse events up to Day 60 |
Countries
Argentina, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Sargramostim Arm Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
Sargramostim: All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days. | 301 |
| Placebo Arm Day 1 - 5: Placebo treatment in addition to standard of care for COVID-19
Placebo: All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days. | 299 |
| Total | 600 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 2 | 0 |
| Overall Study | Death | 1 | 2 |
| Overall Study | Lost to Follow-up | 11 | 13 |
| Overall Study | Not treated | 2 | 0 |
| Overall Study | Withdrawal by Subject | 13 | 21 |
Baseline characteristics
| Characteristic | Total | Sargramostim Arm | Placebo Arm |
|---|---|---|---|
| Age, Continuous | 43.3 years STANDARD_DEVIATION 14.86 | 43.1 years STANDARD_DEVIATION 15.38 | 43.5 years STANDARD_DEVIATION 14.34 |
| Body mass index | 32.5 kg/m^2 STANDARD_DEVIATION 6.08 | 32.3 kg/m^2 STANDARD_DEVIATION 6.15 | 32.6 kg/m^2 STANDARD_DEVIATION 6.03 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 418 Participants | 207 Participants | 211 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 180 Participants | 93 Participants | 87 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 3 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 5 Participants | 1 Participants | 4 Participants |
| Race (NIH/OMB) Black or African American | 70 Participants | 41 Participants | 29 Participants |
| Race (NIH/OMB) More than one race | 6 Participants | 4 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 2 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 4 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) White | 510 Participants | 252 Participants | 258 Participants |
| Region of Enrollment United States | 600 participants | 301 participants | 299 participants |
| Sex/Gender, Customized Female | 325 Participants | 165 Participants | 160 Participants |
| Sex/Gender, Customized Male | 274 Participants | 136 Participants | 138 Participants |
| Sex/Gender, Customized Unknown | 1 Participants | 0 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 297 | 2 / 290 |
| other Total, other adverse events | 46 / 297 | 56 / 290 |
| serious Total, serious adverse events | 13 / 297 | 11 / 290 |
Outcome results
Primary
Number of Participants With an Emergency Room Visit or Hospitalization, or Death by Day 28
Percentage of patients who experience any emergency room visit or hospitalization, or death
Time frame: 28 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Sargramostim Arm | Number of Participants With an Emergency Room Visit or Hospitalization, or Death by Day 28 | 21 Participants |
| Placebo Arm | Number of Participants With an Emergency Room Visit or Hospitalization, or Death by Day 28 | 16 Participants |
Secondary
Change From Baseline in Overall Symptom Scores
Change from baseline in overall symptom score as measured by the Symptom Score Questionnaire on Day 7, Day 14 and Day 28. The overall symptom score is the sum of 14 individual symptom scores from Symptom Score Questionnaire. Individual symptom scores correspond to the following responses: None = 0, Mild = 1, Moderate = 2, Severe = 3; None = 0, 1-2 times = 1, 3-4 times = 2, 5 or more times = 3; Same as usual = 0, Less than usual = 1, No sense = 2. The lowest score could be 0, and the highest score could be 42. Patients with higher scores have more severe symptoms from COVID-19.
Time frame: Day 7, 14, and 28
Population: The Full Analysis Set was used
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Sargramostim Arm | Change From Baseline in Overall Symptom Scores | Day 7 | -7.7 score on a scale | Standard Deviation 7.02 |
| Sargramostim Arm | Change From Baseline in Overall Symptom Scores | Day 14 | -11.7 score on a scale | Standard Deviation 6.62 |
| Sargramostim Arm | Change From Baseline in Overall Symptom Scores | Day 28 | -13.8 score on a scale | Standard Deviation 6.69 |
| Placebo Arm | Change From Baseline in Overall Symptom Scores | Day 7 | -6.7 score on a scale | Standard Deviation 7.33 |
| Placebo Arm | Change From Baseline in Overall Symptom Scores | Day 14 | -10.6 score on a scale | Standard Deviation 7.35 |
| Placebo Arm | Change From Baseline in Overall Symptom Scores | Day 28 | -13.3 score on a scale | Standard Deviation 7.19 |
Secondary
Disease Progression Based on NIAID Score
Proportion of patients with any progression of disease as determined by a ≥ 2-point increase from baseline in the National Institute of Allergy and Infectious Disease (NIAID) Ordinal Scale up to Day 28, and Day 60. The NIAID Ordinal Scale is a 1-8 scale and is an assessment of clinical status on a given study day. A score of 1 indicates the patient is not hospitalized and has no limitations on activities. A score of 8 indicates the patient has died.
Time frame: Day 28 and Day 60
Population: The Full Analysis Set was used for analysis
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Sargramostim Arm | Disease Progression Based on NIAID Score | By Day 28 | 14 Participants |
| Sargramostim Arm | Disease Progression Based on NIAID Score | Day 29-60 | 0 Participants |
| Sargramostim Arm | Disease Progression Based on NIAID Score | No COVID-19 progression | 287 Participants |
| Placebo Arm | Disease Progression Based on NIAID Score | By Day 28 | 14 Participants |
| Placebo Arm | Disease Progression Based on NIAID Score | Day 29-60 | 0 Participants |
| Placebo Arm | Disease Progression Based on NIAID Score | No COVID-19 progression | 285 Participants |
Secondary
Number of Participants With Adverse Events
Adverse events up to Day 60
Time frame: 60 days
Population: Safety population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Sargramostim Arm | Number of Participants With Adverse Events | 59 Participants |
| Placebo Arm | Number of Participants With Adverse Events | 67 Participants |
Secondary
Time to Disease Progression Based on NIAID Score
Time to progression of disease as determined by a ≥ 2-point increase in the NIAID ordinal scale up to Day 28, and Day 60. The NIAID ordinal scale is a 1-8 scale and is an assessment of clinical status on a given study day. A score of 1 indicates the patient is not hospitalized and has no limitations on activities. A score of 8 indicates the patient has died.
Time frame: Day 28 and Day 60
Population: Full Analysis Set
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Sargramostim Arm | Time to Disease Progression Based on NIAID Score | NA Days |
| Placebo Arm | Time to Disease Progression Based on NIAID Score | NA Days |